ID   CoCM-1
AC   CVCL_1127
SY   CoCM1; COCM1
DR   CLO; CLO_0009959
DR   BioSample; SAMN03470823
DR   cancercelllines; CVCL_1127
DR   ChEMBL-Cells; CHEMBL3308133
DR   ColonAtlas; CoCM1
DR   Cosmic; 910783
DR   Cosmic; 1479618
DR   Cosmic; 2301966
DR   EGA; EGAS00001002554
DR   GEO; GSM827287
DR   GEO; GSM1346832
DR   GEO; GSM1448167
DR   IARC_TP53; 21267
DR   JCRB; JCRB0257
DR   LINCS_LDP; LCL-1196
DR   PRIDE; PXD005354
DR   PRIDE; PXD005355
DR   Progenetix; CVCL_1127
DR   Wikidata; Q54813961
RX   PubMed=2570482;
RX   PubMed=8348978;
RX   PubMed=9290701;
RX   PubMed=16418264;
RX   PubMed=18258742;
RX   PubMed=20215515;
RX   PubMed=20570890;
RX   PubMed=20606684;
RX   PubMed=24755471;
RX   PubMed=25877200;
RX   PubMed=25926053;
RX   PubMed=29101300;
CC   Population: Japanese.
CC   Doubling time: 45 hours (PubMed=2570482); ~34 hours (Note=Lot 06302006), ~59 hours (Note=Lot 12222011) (JCRB=JCRB0257).
CC   Microsatellite instability: Stable (MSS) (PubMed=24755471; PubMed=25926053).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Arg1023Gln (c.3068G>A); Zygosity=Unspecified (PubMed=20570890).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=16418264).
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Colon, descending; UBERON=UBERON_0001158.
ST   Source(s): JCRB=JCRB0257; PubMed=25877200; PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 10
ST   D16S539: 12,13
ST   D18S51: 14
ST   D21S11: 29,31
ST   D3S1358: 16,18
ST   D5S818: 11,12
ST   D7S820: 9,11
ST   D8S1179: 13
ST   FGA: 24
ST   Penta D: 9
ST   Penta E: 18,20
ST   TH01: 7,9
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 32
//
RX   PubMed=2570482; DOI=10.1007/BF02899077;
RA   Kataoka H., Nabeshima K., Komada N., Koono M.;
RT   "New human colorectal carcinoma cell lines that secrete proteinase
RT   inhibitors in vitro.";
RL   Virchows Arch. B. Cell. Pathol. Incl. Mol. Pathol. 57:157-165(1989).
//
RX   PubMed=8348978; DOI=10.1016/0014-5793(93)80946-R;
RA   Kataoka H., Seguchi K., Inoue T., Koono M.;
RT   "Properties of alpha 1-antitrypsin secreted by human adenocarcinoma
RT   cell lines.";
RL   FEBS Lett. 328:291-295(1993).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=16418264; DOI=10.1073/pnas.0510146103; PMCID=PMC1327731;
RA   Liu Y., Bodmer W.F.;
RT   "Analysis of p53 mutations and their expression in 56 colorectal
RT   cancer cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).
//
RX   PubMed=18258742; DOI=10.1073/pnas.0712176105; PMCID=PMC2268141;
RA   Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.;
RT   "Cell growth, global phosphotyrosine elevation, and c-Met
RT   phosphorylation through Src family kinases in colorectal cancer
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192; PMCID=PMC2943514;
RA   Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S.,
RA   Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.M.,
RA   Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M.,
RA   Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.;
RT   "Genomic and biological characterization of exon 4 KRAS mutations in
RT   human cancer.";
RL   Cancer Res. 70:5901-5911(2010).
//
RX   PubMed=20606684; DOI=10.1038/sj.bjc.6605780; PMCID=PMC2920028;
RA   Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.;
RT   "5-fluorouracil response in a large panel of colorectal cancer cell
RT   lines is associated with mismatch repair deficiency.";
RL   Br. J. Cancer 103:340-346(2010).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//
RX   PubMed=29101300; DOI=10.15252/msb.20177701; PMCID=PMC5731344;
RA   Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R.-S.,
RA   Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S.,
RA   Johnstone E., Domingo E., Kerr D.J., Jesinghaus M., Slotta-Huspenina J.,
RA   Weichert W., Knapp S., Feller S.M., Kuster B.;
RT   "Pharmacoproteomic characterisation of human colon and rectal
RT   cancer.";
RL   Mol. Syst. Biol. 13:951-951(2017).
//